Freshfields Advises on 4D Molecular Therapeutics $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

"Freshfields advised Leerink Partners, Evercore ISI and Cantor as joint book-running managers, and RBC Capital Markets as co-manager, in 4D Molecular Therapeutics’ $100 million underwritten offering of common stock and pre-funded warrants, which closed on November 7, 2025."

Freshfields advised Leerink Partners, Evercore ISI and Cantor as joint book-running managers, and RBC Capital Markets as co-manager, in connection with 4D Molecular Therapeutics’ $100 million underwritten offering of common stock and pre-funded warrants. The offering comprised 8,385,809 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,128,949 shares of common stock. The shares of common stock were sold at $10.51 per share and the pre-funded warrants were sold at $10.5099 per pre-funded warrant, reflecting the per-share price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. The offering closed on November 7, 2025. Freshfields represented Leerink Partners, Evercore ISI and Cantor as joint book-running managers, and RBC Capital Markets as co-manager, with a team composed by: capital markets partners Phillip Stoup and Jacqueline Marino; senior associate Katherine Kim; associates Yunah Ko and Breandan Mchale; partner Vinita Kailasanath and associate Juliana Zhang on intellectual property matters; and counsel Jay Cosel on tax matters.

Freshfields Advises on 4D Molecular Therapeutics $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads